Form 4: CG Oncology GC Joshua Patterson Receives Stock Options

General Counsel and Chief Compliance Officer Joshua F. Patterson was granted 45,266 employee stock options by CG Oncology, Inc.

Summary

• Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., received a grant of 45,266 employee stock options.
• The options have an exercise price of $67.68 per share.
• The grant date is April 15, 2026, with an expiration date of April 14, 2036.
• The options vest monthly over a 48-month period starting from the vesting commencement date of April 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Aligns the interests of the General Counsel and Chief Compliance Officer with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the Reporting Person's continuous service to the Issuer, creating potential retention risk if the individual departs.

Future Outlook

The options vest over a four-year period, indicating a long-term retention strategy for the executive.

Industry Context

StockSavvy.ai notes that equity grants to key executives in the biotechnology sector are standard practice to ensure leadership alignment with clinical and commercial milestones.

Comparison to Industry Standards

• The use of 48-month monthly vesting schedules is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on a monthly basis over the next 48 months.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Options, Executive Compensation